<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04289649</url>
  </required_header>
  <id_info>
    <org_study_id>K-924-02</org_study_id>
    <nct_id>NCT04289649</nct_id>
  </id_info>
  <brief_title>K-924 Phase III Confirmatory Study</brief_title>
  <official_title>A Phase III, Multicenter, Randomized, Clinial Trial to Evaluate the Efficacy and Safety of K-924 in Patienta With Hypercholesterolemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kowa Company, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kowa Company, Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter, active-controlled, randomized, double-blind comparative study to compare the
      efficacy and safety of K-924 LD tablet or K-924 HD tablet to pitavastatin 2 mg or 4 mg in
      patienta with hypercholesterolemia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2, 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy : % change from baseline in LDL-C (Friedewald formula) (mg / dL)</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy : % change or change from baseline in LDL-C (mg / dL)</measure>
    <time_frame>From baseline upto week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy : % change or change from baseline in non-HDL-C (mg / dL)</measure>
    <time_frame>From baseline upto week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy : % change or change from baseline in HDL-C (mg / dL)</measure>
    <time_frame>From baseline upto week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy : % change or change from baseline in Total Cholesterol (mg / dL)</measure>
    <time_frame>From baseline upto week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy : % change or change from baseline in TG (mg / dL)</measure>
    <time_frame>From baseline upto week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">288</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>K-924 LD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>K-924 LD tablet once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>K-924 HD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>K-924 HD tablet once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pitavastatin 2 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>K-924 LD Placebo tablet once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pitavastatin 4 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>K-924 HD Placebo tablet once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>K-924 LD</intervention_name>
    <description>Pitavastatin 2 mg / Ezetimibe 10 mg tables</description>
    <arm_group_label>K-924 LD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>K-924 HD</intervention_name>
    <description>Pitavastatin 4 mg / Ezetimibe 10 mg tables</description>
    <arm_group_label>K-924 HD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>K-924 LD Placebo</intervention_name>
    <description>Pitavastain 2 mg</description>
    <arm_group_label>Pitavastatin 2 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>K-924 HD Placebo</intervention_name>
    <description>Pitavastain 4 mg</description>
    <arm_group_label>Pitavastatin 4 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with hypercholesterolemia had to be age 20 years or older at written informed
             consent (ICF)

          2. Patients who have been on a diet and / or exercise regimen more than 12 weeks before
             the screening

          3. Those whose LDL-C (Friedewald formula) at the screening any of the following in the
             category classification based on Japan Atherosclerosis Society guidelines for
             prevention Atherosclerotic Cardiovascular Disease 2017

               -  Low risk of primary prevention : LDL-C =&gt; 160 mg/dL

               -  Medium risk of primary prevention : LDL-C =&gt; 140 mg/dL

               -  High risk of primary prevention : LDL-C =&gt; 120 mg/dL

        Exclusion Criteria:

          1. Patients with a history of myopathy or rhabdomyolysis due to pitavastatin or ezetimibe

          2. Patients with a history of hypersensitivity due to pitavastatin or ezetimibe

          3. Patients with severe liver damage (Child Pugh Class B or higher) or biliary
             obstruction

          4. Pregnant women, lactating women, women planning to become pregnant or lactating during
             the study period, or pregnant women who do not use specific contraceptive methods

          5. Patients whose CK is 3 times or more of the upper limit of the reference value at
             screening

          6. Patients whose AST and ALT is 2 times or more of the upper limit of the reference
             value at screening

          7. Patients wiht type 1 diabetes or uncontrolled type 2 diabetes as defined HbA1c 8% or
             more at screening

          8. Patients with uncontrolled hypertension as defined systolic blood pressure of 160 mmHg
             or more or diastolic blood pressure of 100 mmHg or more at screening

          9. Patients with eGFR of less than 30 mL / min / 1.73 mÂ² at screening or dialysis

         10. Patients with heart failure class III or higher according to NYHA cardiac function
             classification

         11. Patients with uncontrolled arrhythmia

         12. Patients with uncontrolled metabolic endocrine disease

         13. Patients with a history of coronary artery disease or patient with familial
             hypercholesterolemia

         14. Patients with malignant tumors or who are judged to have a high possibility of relapse

         15. Patients who have collected 200 mL or more within 4 weeks before screening, 400 mL or
             more of blood within 12 weeks for males or 16 weeks for females, or within 2 weeks for
             (Plasma component / platelet component)

         16. Persons with a history of severe drug allergy (anaphylactic shock, etc.)

         17. Patients who need contraindicated drugs during the study period after obtaining
             consent

         18. Patients with TG of 400 mg / dL or more at screening

         19. Patients who have LDL apheresis

         20. Patients with malabsorption or history, or who have undergone gastrointestinal surgery
             (excluding appendectomy, hernia treatment, etc.) that may affect absorption.

         21. Patients with Alcohol or drug addiction

         22. Patients who participate in other clinical trials within 16 weeks prior to study drug
             administration and who are administered non-placebo investigational drugs, or who
             participate in other clinical trials concurrently with this study

         23. Patients who have received K-924

         24. Patients who judged to be inappropriate by the Investigator or Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Takanori Meikari</last_name>
    <email>ctrdinfo@kowa.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical Corporation Heishinkai OCROM Clinic</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Heishinkai OPHAC Hospital</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Heishinkai ToCROM Clinic</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 27, 2020</study_first_submitted>
  <study_first_submitted_qc>February 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2020</study_first_posted>
  <last_update_submitted>June 9, 2020</last_update_submitted>
  <last_update_submitted_qc>June 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

